From new partnerships to product launches, here are 12 key developments in orthobiologics during the first quarter of 2025.
1. Medtronic and Kuros Biosciences signed a strategic agreement to support sales of the MagnetOs bone graft technology. Under the agreement Medtronic will act as the exclusive sales agent of MagnetOs for Kuros Biosciences USA, Inc. in mutually agreed upon sales territories for use in spine surgeries. Kuros Biosciences, which is behind MagnetOs, will support Medtronic’s sales team and be responsible for contracts and partnerships.
2. Ventris Medical earned FDA 510(k) clearance for its Backpack bone graft containment system. Backpack is a porous biologic scaffold designed for orthopedic and spinal fusions. It is available in two versions – one prefilled with Allocell AF allograft fibers and one prefilled with surface activated amplify granules.
3. Royal Biologics and Fair Winds Medical partnered to distribute spine and orthopedic biologics.
4. SurGenTec earned FDA 510(k) clearance for its OsteoFlo HydroFiber to be used as a stand-alone equivalent to autografts in spine surgeries.
5. LifeNet Health and Johnson & Johnson MedTech launched the PliaFX Flo demineralized bone matrix.
6. Acuitive Technologies named Wayne Berberian, MD, as its chief medical officer.
7. Jamie Antoine, MD, of Seattle-based Proliance Surgeons performed the first case using CartiHeal’s Agili-C implant in Washington state.
8. Stem cell therapies can be effective for treating discogenic low back pain, according to a study published in the January 2025 issue of the International Journal of Spine Surgery.
9. The global spine biologics market is on pace to have a 17.51% compound annual growth rate from 2024 to 2034.
10. Paul Fleissner, MD, of Fairlawn, Ohio-based Crystal Clinic Orthopaedic Center is the first surgeon to use the RejuvaKnee implant for meniscus repair.
11. Atreon Orthopedics earned FDA 510(k) clearance for the BioCharge autobiologic matrix and launched the new product. The company also earned expanded FDA 510(k) clearance for its Rotium bioreabsorbable wick.12. Miach Orthopaedics’ BEAR (bridge-enhanced ACL restoration) implant is now available to treat children and adolescents with anterior cruciate ligament tears after the FDA expanded its clearance.